| Project/Area Number |
23659158
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General medical chemistry
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
SENJU Satoru 熊本大学, 大学院・生命科学研究部, 准教授 (50274709)
|
|---|
| Research Collaborator |
TAKAMATSU Koutaro 熊本大学, 大学院・生命科学研究部, 大学院・・生、医員
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | アルツハイマー病 / iPS 細胞 / マクロファージ / アミロイドβ / iPS細胞 / 治療 / 細胞治療 / アミロイドベータ / 疾患モデルマウス |
|---|
| Research Abstract |
The purpose of this study is to generate macrophages with acapacity to degrade or remove amyloid-・protein, which is known to be the causative agentof Alzheimer ’ s disease.Before this project, we had established a technology to generate functionalphagocytes (macrophages) from mouse and human iPS cells. In the current study , wegenerated macrophages expressing Fc-receptor-fused form of single chain antibody specificto amyloid-・. In addition, we made macrophages expressing neprilysin, a protease reportedto be highly potent in degradation of amyloid-・. We administered the genetically modifiediPS cell-derived macrophages into model mice of Alzheimer ’ s disease, and evaluate whetherthey could reduce the level of amyloid-・in vivo.
|
